1 253 clinically stable COPD patients (4-year
median follow-up).
2 ally meaningful improvement in RFS at 3-year
median follow-up.
3 ort an updated RFS analysis at the 3.05-year
median follow-up.
4 analytic cohort comprised 6804 EVR patients (
median follow-up:
1.85 years; interquartile range: 0.82-
5 Results During a 4.8-year
median follow-up,
136 (12%) first major adverse cardiac
6 cardia: n = 631) among 468,952 participants (
median follow-up,
15.5 years).
7 (1983-2018; mean age at baseline = 46 years;
median follow-up,
19 years).
8 which 33 patients were hospitalized for HF (
median follow-up,
2.0 years), was used for further candi
9 evaluated, with follow-up through May 2018 (
median follow-up,
2.63 years).
10 2-3.22 years) and 1889 open repair patients (
median follow-up:
2.62 years; interquartile range: 1.13-
11 The overall survival rate after HSCT (
median follow-up,
20 months) was 70.8% (17 of 24 patient
12 (88%) completed three visits over 9 months (
median follow-up 226 days [IQR 198-357]).
13 acy and safety were key secondary endpoints (
median follow-up,
24.3 months).
14 ciated with incident ASCVD (n = 1386 events;
median follow-up,
25.2 years; hazard ratio [HR], 1.06 [9
15 During follow-up (
median follow-up,
3.1 years; interquartile range, 2.7-3.
16 of 1263 out of 13 885 (9.1%) patients died (
median follow-up:
30 months).
17 ths from the last patient randomly assigned (
median follow-up,
32.0 months for nivolumab and 10.9 mon
18 urvival (OS) were 57% and 71%, respectively (
median follow-up,
32.1 months).
19 ad testing at age 11 years (302 [54%] male) (
median follow-up,
34 [interquartile range, 33.7-34.7] ye
20 R-CHOP, 377 both regimens used in the study;
median follow-up 39.0 months [IQR 25.5-52.8]).
21 (quartile 4) were associated with long-term (
median follow-up 4.7 years) all-cause mortality (adjuste
22 linkage to national TB surveillance records (
median follow-up 4.7 yr).
23 on individuals with reduced kidney function (
median follow-up 4.9 years, 45% men, 19% with CVD, and 7
24 cardiac resynchronization therapy patients (
median follow-up,
4.2 years [interquartile range, 2.7-6.
25 age at presentation 6.9 years, 0-58.7 years;
median follow-up 5.4 years, 1.1-43.7 years), 23 (71.9%)
26 ng 405 uveitic at-risk eyes of 232 patients (
median follow-up =
6.9 years), 40% (79/196) of eyes assi
27 Among the 30-day survivors of brain abscess (
median follow-up 7.6 years [IQR 2.2-15.5]), new-onset ep
28 07 CHD and 3253 stroke events were recorded (
median follow-up,
8.1 years).
29 At 96 months
median follow-up,
94% versus 12% remained MRD free.
30 Median follow-up after diagnosis was 34 months (IQR: 17
31 191), and all-cause mortality (n=527; 3-year
median follow-up after MI).
32 uximab therapy and none of them had relapse (
median follow-up after remission = 3.6 years).
33 Median follow-up among survivors was 11 years.
34 At the time of data cutoff on Aug 6, 2019,
median follow-up among survivors was 13.0 months (IQR 11
35 Median follow-up at data cutoff (April 5, 2019) was 35.7
36 Median follow-up at the time of data cutoff was 2.3 mont
37 During 6.9-year
median follow-up,
CHIP associated with increased inciden
38 At 5 years of
median follow-up,
DFS was not different between DC (n =
39 At the data cutoff date on March 30, 2020,
median follow-up duration was 6.2 months (IQR 3.5-8.1).
40 ational Institutes of Health were collected (
median follow-up duration, 4.5 years).
41 Hospital, Thailand, were collected annually (
median follow-up duration, 7.5 years).
42 Median follow-up durations were 13.2 months [IQR 6.2-19.
43 Median follow-up for alive patients was 7.9 months.
44 The
median follow-up for all patients was 16 months (95% CI
45 Median follow-up for overall survival for all 344 patien
46 Median follow-up for progression-free survival at data c
47 Median follow-up for progression-free survival was 6.9 m
48 Median follow-up for survival was 11.8 months (IQR 6.1-1
49 The overall
median follow-up for the CCSS cohort was 23.9 years (IQR
50 Median follow-up from breast cancer diagnosis was 8.3 ye
51 non-cardiovascular hospitalizations during a
median follow up of 9.6 years.
52 During a
median follow-up of 0.4 (interquartile range, 0.1-1.4) y
53 im analysis with 42 evaluable patients and a
median follow-up of 0.8 years (IQR 0.3-1.6) in the pazop
54 At the
median follow-up of 1 year, high-certainty evidence show
55 ents (80%) developed PDAC recurrence after a
median follow-up of 10 months (interquartile range 5-17)
56 Over a
median follow-up of 10.2 years, mortality was highest fo
57 Over a
median follow-up of 10.2 years, of the 13 204 eyes, 34.0
58 The outcome occurred in 98 KTRs during a
median follow-up of 10.7 years.
59 With a
median follow-up of 11 months, the 1-year progression-fr
60 After a
median follow-up of 11 years (range 1 mo-25 yrs), sympto
61 At data cutoff (Oct 1, 2018), after a
median follow-up of 11.0 months (IQR 6.8-23.0), all pati
62 Over a
median follow-up of 11.1 years, EF recovery was associat
63 Over a
median follow-up of 11.4 years, there were 1550 deaths (
64 At a
median follow-up of 12 months, the objective response ra
65 At a
median follow-up of 12.3 months (range, 7.0 to 32.3), 57
66 During a
median follow-up of 12.6 years, 196 (4.95%) patients wit
67 During a
median follow-up of 13 years, 2128 participants died, in
68 At a
median follow-up of 13.8 months (IQR 7.8-19.0), median d
69 After a
median follow-up of 14.5 years, there were 60 deaths, in
70 During a
median follow-up of 14.7 years, 2,030 incident cancer ca
71 227 participants (9.5%), respectively, over
median follow-up of 15.5 years (interquartile range [IQR
72 19.8% (20,766/104,719) of patients during a
median follow-up of 152 (IQR: 61-265) weeks.
73 At a
median follow-up of 16 days, the overall case fatality r
74 With
median follow-up of 16 months, median duration of respon
75 isease and 10.3 +/- 1.0 in F3 disease, and a
median follow-up of 16 months.
76 During
median follow-up of 16 years, 60.0% of relatives attende
77 Over a
median follow-up of 162 days, 51 (51%) experienced MACE.
78 zed trial conducted from 2008 to 2012 over a
median follow-up of 17.0 months in 966 sites (52 countri
79 with advanced ACC and herein report after a
median follow-up of 17.8 months (range, 5.4 months to 34
80 In 79 073 patients, at a
median follow-up of 18 months, extended-term DAPT was as
81 At a
median follow-up of 18 months, overall survival was 95%
82 endometrial carcinoma were enrolled, with a
median follow-up of 18.7 months.
83 At a
median follow-up of 18.9 months (IQR 10.4-23.8), progres
84 During a
median follow-up of 19.3 months, 152 patients (20.79%) d
85 During a
median follow-up of 2.42 years (interquartile range: 1.0
86 With a
median follow-up of 2.6 years (IQR 1.8-2.9) in the ipili
87 During a
median follow-up of 2.6 years, a primary outcome event o
88 RT subjects and 37 (59%) PSM-controls with a
median follow-up of 2.7 years (quartiles, 0.8-6.1 years)
89 (12 ischaemic and two haemorrhagic) during a
median follow-up of 2.8 years (IQR 1.5-4.6).
90 At a
median follow-up of 20 months (range, 3-54 months), ther
91 During a
median follow-up of 22 months, mean eGFR increased to 43
92 Of the remaining 1376 patients, during a
median follow-up of 22.5 days, 811 (58.9%) received hydr
93 were associated with overall mortality over
median follow-up of 23.1 years (P<=0.003 for both).
94 With
median follow-up of 23.5 months (range, 0.6-40.9 months)
95 nd 17 patients remained cancer free during a
median follow-up of 24 mo after nCRT.
96 eoperative SEQ of - 11.02 +/- 0.81 D, with a
median follow-up of 24 months.
97 ited States, with a mean age of 54 years and
median follow-up of 24 years.
98 At a
median follow-up of 24.2 months in treatment-naive patie
99 Over a
median follow-up of 24.5 (interquartile range, 14.8-33.4
100 With a
median follow-up of 26 months, the 2-year overall surviv
101 Within
median follow-up of 27 months, 43 and 42 patients switch
102 Over a
median follow-up of 27 y, 2131 incident CAD cases accrue
103 With a
median follow-up of 27.4 months (IQR 26.0-29.7), 13 (93%
104 At a
median follow-up of 28 months, del(17p) and mutated TP53
105 87 eyes of 54 patients were assessed with a
median follow-up of 28 months.
106 dian overall survival was not reached at the
median follow-up of 28.3 months.
107 As of July 2, 2019, at a
median follow-up of 28.4 months (IQR 17.7-36.8), median
108 During a
median follow-up of 3 years, 34 subjects (21.3%) experie
109 During
median follow-up of 3.0 (IQR 1.2-4.8) years, 613 (41%) p
110 RTI-, 30% PI-, and 23% INSTI-based cART with
median follow-up of 3.0, 2.3, and 1.6 years, respectivel
111 After a
median follow-up of 3.1 years, the achieved LDL-C concen
112 tion, and 57% had no recurrence to date with
median follow-up of 3.1-years.
113 During a
median follow-up of 3.6 years (interquartile range: 1.3
114 During a
median follow-up of 3.7 years, participants without base
115 osed individuals, 12 experienced MACE over a
median follow-up of 3.75 years.
116 ohort study within the PREDIMED Study during
median follow-up of 3.8 y.
117 During the
median follow-up of 3.8 years (95% confidence interval,
118 Over a
median follow-up of 30 months, 1,148 incidents of MACE (
119 ratio 0.45, 95% CI 0.30-0.68; p=0.0001) at a
median follow-up of 30.3 months (IQR 18.0-47.5).
120 At a
median follow-up of 31.4 mo, median overall survival was
121 e for 120 of the 122 persons on board over a
median follow-up of 32.5 days (range, 18.8 to 50.5 days)
122 years; interquartile range, 79-88 years) and
median follow-up of 333 days.
123 33 HIV-negative tuberculosis contacts with a
median follow-up of 346 days, this signature achieved a
124 Over a
median follow-up of 35 months, risk of total HF hospital
125 ment duration of 23 months (IQR 10-47) and a
median follow-up of 36 months (IQR 22-53).
126 At a
median follow-up of 36 months, Kaplan-Meier overall surv
127 onset cCMVI-related HL was detected during a
median follow-up of 36 months.
128 total cohort (n = 15 LR, n = 3 distant), at
median follow-up of 36.7 months.
129 Eight hundred thirty-six patients with a
median follow-up of 37 months (interquartile range 30-48
130 With a
median follow-up of 37 months (range 1-62), no differenc
131 prognosticators of ischemic stroke during a
median follow-up of 37.6 months.
132 Over a
median follow-up of 4 years, the incidence of new-onset
133 hree patients (50%) are currently alive with
median follow-up of 4.0-years (11 months-11.8 years).
134 During a
median follow-up of 4.4 years, 179 (23%) received a kidn
135 With a
median follow-up of 4.5 years, the 5-year overall surviv
136 After a
median follow-up of 4.7 years (range 0 to 11.2 years), t
137 kg/m(2); 43% men; 48% with diabetes) after a
median follow-up of 4.8 years.
138 With a
median follow-up of 4.9 years (IQR 3.9-8.4), median over
139 After a
median follow-up of 4.9 years, patients with negative, l
140 After a
median follow-up of 4.9 years, the overall mortality rat
141 With a
median follow-up of 4.92 years (range, 1.1-7.7 years), o
142 During a
median follow-up of 40.1 months (interquartile range, 26
143 At a
median follow-up of 40.1 months (IQR 37.4-43.1), a signi
144 After a
median follow-up of 42 months (IQR 22-67), 33 (28%) of t
145 rogression of conjunctival scarring during a
median follow-up of 42 months (range, 8-100 months) and
146 During a
median follow-up of 43 (3-57) months after DAA start, 36
147 With a
median follow-up of 44 months (26-53), 4-year event-free
148 At a
median follow-up of 44 months (IQR 20-61), overall survi
149 After a
median follow-up of 47.5 months (IQR 42.3-53.3), inciden
150 With a
median follow-up of 48.9 months, progression was identif
151 e-free at the time of data censoring, with a
median follow-up of 49.2 months.
152 During a
median follow-up of 5 years (2 to 8 years), the combined
153 At a
median follow-up of 5 years, 37 of 41 (90%) patients wit
154 With a
median follow-up of 5 years, DeltaSUV, as continuous var
155 Over a
median follow-up of 5.0 years, 2,028,062 (67.4%) hospita
156 After a
median follow-up of 5.2 years (interquartile range: 2.2
157 During
median follow-up of 5.4 (IQR 5.1-5.9) years, 8828 partic
158 At the final analysis, with a
median follow-up of 52 months, the projected DFS and OS
159 With a
median follow-up of 53 months (IQR 46-59), no difference
160 With a
median follow-up of 533 days, the 1-year progression-fre
161 Another 11 patients with a
median follow-up of 54 months (range, 15-138 months) wer
162 During a
median follow-up of 56 (interquartile range: 28 to 106 m
163 After
median follow-up of 56 months, 5-year progression-free s
164 At a
median follow-up of 58.7 months, EFS and OS were 84.5% a
165 Disease outcomes with a
median follow-up of 6 years among young women with N0 di
166 f benzodiazepines or Z-drugs, and during the
median follow-up of 6.1 years (interquartile range, 2.7-
167 Over a
median follow-up of 6.2 years (interquartile range: 2.7
168 At data cutoff (May 31, 2019), at a
median follow-up of 6.3 months (IQR 3.2-8.2) in the ripr
169 We included 1,612,629 patients with a
median follow-up of 6.3 years.
170 ths, and 116 cancer deaths occurred during a
median follow-up of 6.4 years.
171 At a
median follow-up of 6.5 years (IQR 4.9-7.9), 5-year even
172 With a
median follow-up of 6.6 months (IQR 5.5-8.5) for the ate
173 At a
median follow-up of 6.6 years, there were 8 major advers
174 oke 13.3%; and major bleeding 13.2% during a
median follow-up of 632 days (interquartile range: 187 t
175 At a
median follow-up of 68 months (interquartile range, 58-7
176 At a
median follow-up of 7.5 months (IQR 6.5-9.3), overall re
177 At a
median follow-up of 70 months, rates of 5-year overall s
178 At a
median follow-up of 71.5 months (IQR 71.3 to 71.7), the
179 With
median follow-up of 72.3 months (IQR 72.2-72.5), 2584 de
180 During a
median follow-up of 8 y, 200 (9%) participants were diag
181 Over a
median follow-up of 8 years, 2,583 participants develope
182 During a
median follow-up of 8 years, indigenous recipients were
183 The study included 432 patients with a
median follow-up of 8.65 years.
184 At a
median follow-up of 9 months (IQR 5-23), at a second pla
185 With a
median follow-up of 9 years, 2 patients (1.3%; 1 patient
186 8; autologous: n = 676) participated, with a
median follow-up of 9.3 years from BMT.
187 After a
median follow-up of 92 months (range, 1-131 months), 3-y
188 With a
median follow-up of 96 months, the 5-year PFS was 67% (9
189 merican Heart Association guidelines, with a
median follow-up of at least 2 years and data on older p
190 In these exploratory analyses over a
median follow-up of more than 2 years, rucaparib mainten
191 The
median follow-up of surviving patients was 6.3 months (r
192 With a 2.9-year
median follow-up,
OS improved from 33% (46-68%) for HCT
193 ce-free survival (RFS) events at a 1.25-year
median follow-up,
pembrolizumab prolonged RFS (hazard ra
194 Median follow-up per study ranged from 1.0 to 10.6 years
195 L of which 371 (36%) received an RT during a
median follow-up period of 2.5 (1.4-4.1) years.
196 f 960 subjects had an ischemic stroke over a
median follow-up period of 2.5 years.
197 79 patients (2.15 IEps per patient) during a
median follow-up period of 3 years.
198 6 PHIVA were included in the analysis with a
median follow-up period of 3.0 years, of whom 230 (7.2%)
199 lant year in a cohort of 538 patients with a
median follow-up period of 4.1 years.
200 After a
median follow-up period of 6 years (IQR: 2.3 to 13.9 yea
201 At the data cutoff (Aug 7, 2019), the
median follow-up period was 12.9 months (IQR 6.2-22.9).
202 was 9 days (interquartile range, 5-15 d) and
median follow-up post heart transplantation was 20.7 mon
203 Median follow-up ranged from 60 months to 78 months, wit
204 ow, after a long-term, cumulative 19.6-year (
median) follow-up,
the significant reduction in deaths a
205 821), median exposure (3.3 vs 1.8 years) and
median follow-up time (62 vs 26 months) have increased.
206 After re-DMEK (
median follow-up time 14.5 [42.5] months), mean BCVA imp
207 The overall
median follow-up time after diagnosis was 52.7 months fo
208 Median follow-up time for the HPV group was 11.1 years (
209 The mean age was 66.6 +/- 19.2 years with a
median follow-up time of 147 days.
210 After a
median follow-up time of 23 months (range, 6.1-54.7 mont
211 ts were enrolled at eight dose levels with a
median follow-up time of 44.6 months; data cutoff was Ja
212 brain abscess patients (37% females) with a
median follow-up time of 5.9 years (interquartile range
213 During a
median follow-up time of 6 (25th-75th, 4-10) years, 22 p
214 During a
median follow-up time of 62.5 months, 564 of the 3,478 p
215 After a
median follow-up time of 696 days (interquartile range 1
216 Over a
median follow-up time of 7 years, 74 of 103 treated pati
217 After a
median follow-up time of 7.6 years, the previously descr
218 a diagnosis of CD from 2008 to 2017, with a
median follow-up time of 7.8 years.
219 (n = 1,215) and replacement (n = 467) for a
median follow-up time of 8.7 years.
220 Median follow-up time was 1467 days (IQR 1029-2052) and
221 Median follow-up time was 17 months (range, 7 to 30 mont
222 Median follow-up time was 28 (interquartile range 19-41)
223 The
median follow-up time was 38 months (95% confidence inte
224 The
median follow-up time was 5.0 years, and the proportions
225 Median follow-up time was 6.1 years.
226 The
median follow-up time was 7.4 months, with an interquart
227 Median follow-up time was 81.1 months.
228 After propensity matching, the respective
median follow-up times were 3.72 years and 3.76 years.
229 Median follow-up was 1.1 (interquartile range 0.4-3.3) y
230 Median follow-up was 10 months (IQR 6-15).
231 d March 6, 2017, 616 patients were enrolled;
median follow-up was 10.5 months (range 0.2-20.4) as of
232 Median follow-up was 10.7 years.
233 Median follow-up was 108 months, interquartile range 66-
234 the analysis, the mean age was 63 years and
median follow-up was 11.3 years.
235 Median follow-up was 12.4 mo (range, 9.7-15.2 mo).
236 Median follow-up was 12.9 months (IQR 8.77-18.76).
237 The
median follow-up was 122.9 months.
238 Median follow-up was 13.2 months (IQR 7.3-20.4) as of da
239 The
median follow-up was 13.7 months (IQR 12.7-14.4).
240 Median follow-up was 14.5 months (range 6-34 months, mea
241 Median follow-up was 14.5 months.
242 Median follow-up was 15.8 years.
243 The
median follow-up was 16 months.
244 Median follow-up was 17.1 months (IQR 6.5-25.3).
245 Median follow-up was 17.4 months.
246 The
median follow-up was 17.8 months (IQR 11.6-21.3).
247 Median follow-up was 18 d (interquartile range 13, 30).
248 nths after receiving BCH-BB694 gene therapy;
median follow-up was 18 months (range, 7 to 29).
249 Median follow-up was 18.0 years, during which 218 men we
250 Median follow-up was 19.0 months (IQR 15.0-23.4).
251 Median follow-up was 19.9 months (IQR 10.7-23.1).
252 The
median follow-up was 2.1 years.
253 Median follow-up was 2.3 years.
254 Median follow-up was 2.6 years.
255 Median follow-up was 2.65 years.
256 Median follow-up was 2.99 years.
257 The
median follow-up was 20.3 months.
258 At data cutoff (April 3, 2020),
median follow-up was 20.6 months (IQR 8.7-24.9) in the a
259 Median follow-up was 21 years (interquartile range 18-24
260 a cutoff for the analysis (Aug 9, 2019), the
median follow-up was 22.0 months (IQR 12.0-26.7) for the
261 olled and 4786 randomly assigned to a group;
median follow-up was 23 months and median dosage 15 mg/w
262 Median follow-up was 25 months, and median number of ave
263 Median follow-up was 253 days (IQR 127-448).
264 Median follow-up was 26 months (range 3-148).
265 Median follow-up was 28.1 months (IQR 22.0-33.6).
266 Median follow-up was 28.6 months.
267 Median follow-up was 29.5 months (IQR 15.6-54.3) for the
268 Median follow-up was 30 days (IQR 27-83).
269 Median follow-up was 31.3 months (95% CI 12.4-35.4) for
270 The
median follow-up was 31.3 months, and median time to rec
271 16,187 patients were identified;
median follow-up was 32 months.
272 Median follow-up was 379 days (IQR 294-392) for deferipr
273 Median follow-up was 38.3 months (IQR 20.7-46.1, range 0
274 Median follow-up was 39.6 months (range, 24.5-69.3) for
275 The
median follow-up was 39.9 months.
276 The
median follow-up was 4.0 (interquartile range = 2.3-6.7)
277 Median age at diagnosis was 1.9 years,
median follow-up was 4.0 years, and 57.2% were male.
278 The
median follow-up was 44 mo.
279 62 years), 35 developed HCC (3.9%), and the
median follow-up was 45 months (range 13-53).
280 Median follow-up was 45 months.
281 Median follow-up was 49 (18-105) months.
282 Median follow-up was 49.07 (0.97-131.67) months, median
283 Median follow-up was 5.33 (IQR, 3.05-7.59) years.
284 The
median follow-up was 5.62 (interquartile range [IQR], 4.
285 ed eighty-five patients were included with a
median follow-up was 5.8 years.
286 Median follow-up was 51 months.
287 The
median follow-up was 59 months, and overall and major re
288 Median age at presentation was 2.8 years and
median follow-up was 6.2 years.
289 Three screening rounds were included, and
median follow-up was 6.6 years for LDCT and 6.5 years fo
290 The
median follow-up was 61.2 months (IQR 53.8-70.0) for the
291 On Feb 6, 2018,
median follow-up was 62.9 months (IQR 58.1-74.1).
292 18) for the final overall survival analysis,
median follow-up was 7.4 months (IQR 3.5-13.9).
293 en (73.9%) (median age, 65.5 years), and the
median follow-up was 7.6 years (interquartile range, 5.7
294 Median follow-up was 8.0 years (interquartile range: 4.0
295 The
median follow-up was 8.5 months (IQR 3.1-12.2).
296 Median follow-up was 8.6 months (IQR 2.5-16.4).
297 The
median follow-up was 82 months.
298 Median follow-up was 9.2 months (IQR 5.6-13.1).
299 Median follow-up was 91.4 months (IQR 75.1-105.6).
300 nd 386 deaths from 8 PTXD trials with 4-year
median follow-up were identified.